TIAA Trust National Association Has $2.99 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

TIAA Trust National Association lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 79.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,387 shares of the medical device company’s stock after selling 147,068 shares during the quarter. TIAA Trust National Association’s holdings in DexCom were worth $2,985,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA boosted its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC raised its position in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter worth about $38,000. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DXCM shares. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Citigroup upped their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.82.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 32,498 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.9 %

NASDAQ:DXCM opened at $72.13 on Thursday. The stock’s fifty day simple moving average is $82.96 and its 200-day simple moving average is $77.07. The firm has a market capitalization of $28.19 billion, a P/E ratio of 50.44, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $141.99.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.